Tolerance to allopregnanolone with focus on the GABA‐A receptor
Open accessThe DOI matches its Crossref record; 25 of the 25 references it cites were found in a registry or an index.
Abstract
Many studies have suggested a relationship between stress, sex steroids, and negative mental and mood changes in humans. The progesterone metabolite allopregnanolone is a potent endogenous ligand of the γ‐amino butyric acid –A (GABA‐A) receptor, and the most discussed neuroactive steroid. Variations in the levels of neuroactive steroids that influence the activity of the GABA‐A receptor cause a vulnerability to mental and emotional pathology. There are physiological conditions in which allopregnanolone production increases acutely (e.g. stress) or chronically (e.g. menstrual cycle, pregnancy), thus exposing the GABA‐A receptor to high and continuous allopregnanolone concentrations. In such conditions, tolerance to allopregnanolone may develop. We have shown that both acute and chronic tolerances can develop to the effects of allopregnanolone. Following the development of acute allopregnanolone tolerance, there is a decrease in the abundance of the GABA‐A receptor α4 subunit and the expression of the α4 subunit mRNA in the ventral‐posteriomedial nucleus of the thalamus. Little is known about the mechanism behind allopregnanolone tolerance and its effects on assembly of the GABA‐A receptor composition. The exact mechanism of the allopregnanolone tolerance phenomena remains unclear. The purpose of this review is to summarize certain aspects of current knowledge concerning allopregnanolone tolerance and changes in the GABA‐A receptors.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Steroid hormone metabolites are barbiturate-like modulators of the GABA receptor
Majewska, M. D., Harrison, N. L., Schwartz, R. D., Barker, J. L., & Paul, S. M. (1986) · Science · doi:10.1126/science.2422758 · Cited by 2,225 · cited 3×
“The GABA-A receptors system is the major inhibitory component of the CNS (Majewska et al., 1986; Rupprecht, 2003), but within this single system there is a number of complications involved in the GABAergic inhibition such as: (i) an excitation component depending on age, cell type, compartment or…”
BackgroundNeurosteroids: endogenous regulators of the GABAA receptor
Belelli, D., & Lambert, J. J. (2005) · Nature reviews. Neuroscience · doi:10.1038/nrn1703 · Cited by 1,159 · cited 4×
“In vitro testing with different techniques are often difficult to compare but indicate that allopregnanolone is active on the GABA-receptor system in the nM range (Harrison et al., 1987; Belelli and Lambert, 2005) while effects of different standard anaesthetics are found in the mM to the mM range with propofol (aroun…”
BackgroundInfluentialPurdy, R. H., Morrow, A. L., Moore, P. H., & Paul, S. M. (1991) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.88.10.4553 · Cited by 951
McKernan, R. M., Rosahl, T. W., Reynolds, D. S., Sur, C., Wafford, K. A., Atack, J. R., Farrar, S., Myers, J., Cook, G., Ferris, P., et al. (2000) · Nature Neuroscience · doi:10.1038/75761 · Cited by 944
Schmidt, P. J., Nieman, L. K., Danaceau, M. A., Adams, L. F., & Rubinow, D. R. (1998) · New England Journal of Medicine · doi:10.1056/nejm199801223380401 · Cited by 765 · cited 2×
“Reintroduction of estradiol or progesterone in women with medically inhibited ovarian hormone production resulted in recurrence of symptoms in women with PMS/PMDD, but not in controls (Schmidt et al., 1998; Segebladh et al., 2009).”
BackgroundEndogenous neurosteroids regulate GABAA receptors through two discrete transmembrane sites
Hosie, A. M., Wilkins, M. E., da Silva, H. M. A., & Smart, T. G. (2006) · Nature · doi:10.1038/nature05324 · Cited by 752 · cited 3×
“The authors suggest that significant receptor activation by neurosteroids relies on occupancy of these domains (Hosie et al., 2006).”
BackgroundGABAA receptor α4 subunit suppression prevents withdrawal properties of an endogenous steroid
Smith, S. S., Gong, Q. H., Hsu, F.-C., Markowitz, R. S., ffrench-Mullen, J. M. H., & Li, X. (1998) · Nature · doi:10.1038/31948 · Cited by 564 · cited 2×
“The changes in the hippocampus seem to be related to up-regulation of the a4 subunit (Smith et al., 1998a,b).”
BackgroundNeurosteroids: biochemistry and clinical significance
Mellon, S. H., & Griffin, L. D. (2002) · Trends in Endocrinology & Metabolism · doi:10.1016/s1043-2760(01)00503-3 · Cited by 538
Pearlstein, T., Howard, M., Salisbury, A., & Zlotnick, C. (2009) · American Journal of Obstetrics and Gynecology · doi:10.1016/j.ajog.2008.11.033 · Cited by 462
Neuroactive steroids: mechanisms of action and neuropsychopharmacological properties
Rupprecht, R. (2003) · Psychoneuroendocrinology · doi:10.1016/s0306-4530(02)00064-1 · Cited by 427
General anaesthetic actions on ligand-gated ion channels
Krasowski, M. D., & Harrison, N. L. (1999) · Cellular and Molecular Life Sciences (CMLS) · doi:10.1007/s000180050371 · Cited by 384 · cited 2×
“Subunit composition appears to determine the pharmacological profile of the different GABA-A receptors where the anaesthetic effect has been the subject of extensive investigations searching for a basic pharmacological mechanism using a number of different in vivo and in vitro experimental techniques (Antkowiak, 1999;…”
BackgroundPatchev, V (1996) · Neuropsychopharmacology · doi:10.1016/s0893-133x(96)00096-6 · Cited by 283 · cited 2×
“Those observations indicate that allopregnanolone might affect the neuroendocrine response to acute stress by influencing the hypothalamus-pituitary-adrenal axis (Patchev et al., 1996; 1997).”
BackgroundJovanovic, J. N., Thomas, P., Kittler, J. T., Smart, T. G., & Moss, S. J. (2004) · The Journal of Neuroscience · doi:10.1523/jneurosci.3606-03.2004 · Cited by 273 · cited 2×
“…can remove the phosphate group within minutes and thus restore receptor function to normal (Gyenes et al., 1994; Brussaard and Koksma, 2002; Jovanovic et al., 2004), but it is doubtful if such rapid mechanisms are involved in the acute tolerance induced by the threshold method as a reduced…”
BackgroundDevaud, L. L., Fritschy, J., Sieghart, W., & Morrow, A. L. (1997) · Journal of Neurochemistry · doi:10.1046/j.1471-4159.1997.69010126.x · Cited by 261 · cited 5×
“…whereas previous observations (Devaud et al., 1997) had shown a significant decrease in a1 and a significant increase in a4 mRNA levels in ethanol dependent (not withdrawing) animals. b2, b1 and g1 mRNA levels increased significantly during ethanol withdrawal (Devaud et al., 1996; 1997).”
BackgroundResultInfluentialDong, E., Matsumoto, K., Uzunova, V., Sugaya, I., Takahata, H., Nomura, H., Watanabe, H., Costa, E., & Guidotti, A. (2001) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.051628598 · Cited by 261 · cited 2×
“A repetitive stress condition in animals has been shown to result in alterations in function and sensitivity of the GABA-A receptor (Deutsch et al., 1994; Serra et al., 2000; Dong et al., 2001; Guidotti et al., 2001; Biggio et al., 2007), pointing to the possibility that chronic stress condition is related to the deve…”
BackgroundBasic pharmacologic mechanisms involved in benzodiazepine tolerance and withdrawal
Bateson, A. (2002) · Current Pharmaceutical Design · doi:10.2174/1381612023396681 · Cited by 240
Luisi, S., Petraglia, F., Benedetto, C., Nappi, R. E., Bernardi, F., Fadalti, M., Reis, F. M., Luisi, M., & Genazzani, A. R. (2000) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jcem.85.7.6675 · Cited by 237 · cited 3×
“…of the GABA steroid allopregnanolone are produced during the luteal phase of the menstrual cycle, during pregnancy and during hormone replacement therapy, which includes progesterone (Luisi et al., 2000; Bicikova et al., 2002; Ottander et al., 2005; Andreen et al., 2006; Nyberg et al., 2007).”
BackgroundAllopregnanolone concentrations and premenstrual syndrome
Monteleone, P., Luisi, S., Tonetti, A., Bernardi, F., Genazzani, A., Luisi, M., Petraglia, F., & Genazzani, A. (2000) · European Journal of Endocrinology · doi:10.1530/eje.0.1420269 · Cited by 186
Sundström, I., Andersson, A., Nyberg, S., Ashbrook, D., Purdy, R. H., & Bäckström, T. (1998) · Neuroendocrinology · doi:10.1159/000054307 · Cited by 182 · cited 17×
“Women with PMDD also show changes in startle response and pre-pulse inhibition during the luteal phase compared with the follicular phase, a phenomenon not seen in controls (Gulinello et al., 2001; Epperson et al., 2007; Kask et al., 2008). fMRI studies show different follicular to luteal phase responses in PMDD patie…”
BackgroundInfluentialSelf-citationLambert, J. J., Belelli, D., Harney, S. C., Peters, J. A., & Frenguelli, B. G. (2001) · Brain Research Reviews · doi:10.1016/s0165-0173(01)00124-2 · Cited by 164 · cited 1×
“It has been suggested that the effects of neurosteroid at physiological concentrations (low nM) may be influenced by the subunit composition of the GABA-A receptor (Lambert et al., 2001).”
BackgroundNeuroadaptive processes in GABAergic and glutamatergic systems in benzodiazepine dependence
Allison, C., & Pratt, J. A. (2003) · Pharmacology & Therapeutics · doi:10.1016/s0163-7258(03)00029-9 · Cited by 160 · cited 1×
“However, the nature and mechanism of these changes are not clear (Allison and Pratt, 2003; Kan et al., 2004; O’Brien, 2005).”
BackgroundNeurosteroids in the context of stress: implications for depressive disorders
Girdler, S. S., & Klatzkin, R. (2007) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2007.05.006 · Cited by 148
Kan, C. C., Hilberink, S. R., & Breteler, M. H. M. (2004) · Comprehensive Psychiatry · doi:10.1016/j.comppsych.2003.12.007 · Cited by 81 · cited 1×
“However, the nature and mechanism of these changes are not clear (Allison and Pratt, 2003; Kan et al., 2004; O’Brien, 2005).”
BackgroundTuveri, A., Paoletti, A. M., Orrù, M., Melis, G. B. B., Marotto, M. F., Zedda, P., Marrosu, F., Sogliano, C., Marra, C., Biggio, G., et al. (2008) · Epilepsia · doi:10.1111/j.1528-1167.2008.01555.x · Cited by 63 · cited 1×
“The serum concentrations of progesterone, pregnenolone and allopregnanolone were not different between groups (Tuveri et al., 2008).”
BackgroundKlein, R. L., & Harris, R. A. (1996) · Japanese Journal of Pharmacology · doi:10.1254/jjp.70.1 · Cited by 41
Cited by
Sex differences in stress-related alcohol use
Peltier, M. R., Verplaetse, T. L., Mineur, Y. S., Petrakis, I. L., Cosgrove, K. P., Picciotto, M. R., & McKee, S. A. (2019) · Neurobiology of Stress · doi:10.1016/j.ynstr.2019.100149 · Cited by 413
Hantsoo, L., & Epperson, C. N. (2020) · Neurobiology of Stress · doi:10.1016/j.ynstr.2020.100213 · Cited by 199
The Role of HPA Axis and Allopregnanolone on the Neurobiology of Major Depressive Disorders and PTSD
Almeida, F. B., Pinna, G., & Barros, H. M. T. (2021) · International Journal of Molecular Sciences · doi:10.3390/ijms22115495 · Cited by 130
“Allopregnanolone plays a regulatory role on the neuroendocrine alterations resulting from the stress response, particularly in conjunction with the feedback mechanisms regulating the HPA axis, mediated by GABAARs.”
BackgroundInfluentialMacKenzie, G., & Maguire, J. (2014) · Psychopharmacology · doi:10.1007/s00213-013-3423-z · Cited by 84
“In fact, recent studies suggest neurosteroid tolerance associated with decreased expression of the GABA A R α 4 subunit (Turkmen et al. 2011) which would have significant implications for the therapeutic potential of neurosteroids.”
Sze, Y., & Brunton, P. J. (2020) · European Journal of Neuroscience · doi:10.1111/ejn.14615 · Cited by 85
Metadata
- Authors
- Turkmen, S., Backstrom, T., Wahlstrom, G., Andreen, L., & Johansson, I.
- Venue
- British Journal of Pharmacology
- Publisher
- Wiley
- Published
- 2010-12-14
- Volume
- 162
- Issue
- 2
- Pages
- 311-327
- ISSN
- 0007-1188 (ISSN-L)
- 1476-5381
- OpenAlex
- W1573410599
- Cited by
- 97
- References
- 25
- FWCI
- 1.87
- Type
- journal article
- Language
- en
- Open access
- green
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.